Fresenius Medical Care AG & Co. KGaAFMSNYSE

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

LivaNova (NASDAQ:LIVN) vs. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Head to Head Comparison

Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) and LivaNova (NASDAQ: LIVN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends. Analyst Recommendations This is

zacks.com

Here's Why Fresenius (FMS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com

FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand

FMS tops Q4 estimates as EPS jumps 59% and margins expand, powered by savings from its FME25+ program despite portfolio-optimization-driven sales pressure.

seekingalpha.com

Fresenius Medical Care AG (FMS) Q4 2025 Earnings Call Transcript

prnewswire.com

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3% Reported operating income grew by 31%, reported net income3 by 82% Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback program Dividend of EUR 1.49 (+3%) planned to be proposed FY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwinds BAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025.

wsj.com

Fresenius Medical Care Shares Drop After Outlook, U.S. Performance Underwhelms

Shares in the dialysis specialist were down 7.1% in European midday trade, with the decline erasing gains since the start of 2026.

reuters.com

Fresenius Medical Care's operating profit surges in Q4

Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.

zacks.com

Here's Why Fresenius (FMS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com

FMS or MASI: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?

zacks.com

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com

3 Undervalued Medical Instrument Stocks Poised to Grow in 2026

FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.

zacks.com

Reasons to Add Fresenius Medical Stock to Your Portfolio Now

FMS' acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.

seekingalpha.com

Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

zacks.com

FMS or MASI: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Masimo (MASI). But which of these two companies is the best option for those looking for undervalued stocks?

prnewswire.com

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion.

zacks.com

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com

Here's Why Fresenius (FMS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com

Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now

FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.

prnewswire.com

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Germany , Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026.

zacks.com

Here's Why Fresenius (FMS) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance